Search

ENPNewswire-December 12, 2024--Lilly s Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio in Patients with ER+, HER2- Advanced Breast Cancer (C)2024 ENPublishing - [...]

ENPNewswire-November 4, 2024--Lilly to Present Results from Phase 3 EMBER-3 study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer [...]

ENPNewswire-August 9, 2024--Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 08082024 - INDIANAPOLIS - Eli Lilly and Company (NYSE: [...]

ENPNewswire-May 1, 2024--Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 30042024 - INDIANAPOLIS - Eli [...]

ENPNewswire-December 6, 2023--Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast [...]

ENPNewswire-October 23, 2023--Eli Lilly and Company - Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio's Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- [...]

ENPNewswire-October 9, 2023--Lilly Announces Details of Presentations at ESMO Congress 2023 (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 06102023 - INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) today announced that [...]

ENPNewswire-September 20, 2023--Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors (C)2023 [...]

ENPNewswire-June 5, 2023--Lilly Highlights Verzenio and Jaypirca) Data at 2023 ASCO Annual Meeting (C)2023 ENPublishing - http://www.enpublishing.co.uk Release date- 02062023 - INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) today [...]

ENPNewswire-October 14, 2021--Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer (C)2021 ENPublishing - http://www.enpublishing.co.uk Release date- 13102021 - Agilent Technologies Inc. (NYSE: [...]

ENPNewswire-April 28, 2021--Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance (C)2021 ENPublishing - http://www.enpublishing.co.uk Release date- 27042021 - INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) announced financial [...]

ENPNewswire-March 18, 2021--Eli Lilly and Company - Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio at St. Gallen Virtual Congress 2021 (C)2021 ENPublishing - http://www.enpublishing.co.uk [...]

ENPNewswire-September 21, 2020--Eli Lilly and Company - Verzenio Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer (C)2020 ENPublishing - [...]

ENPNewswire-June 17, 2020--Eli Lilly and Company - Verzenio Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer (C)2020 ENPublishing - http://www.enpublishing.co.uk Release [...]

ENPNewswire-May 14, 2020--Eli Lilly and Company - Lilly Oncology Showcases Innovation in Cancer Research at ASCO 2020 (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 13052020 - INDIANAPOLIS - Data from 23 [...]

ENPNewswire-September 30, 2019--Eli Lilly and Company - Verzenio Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study (C)2019 [...]

ENPNewswire-July 31, 2019--Lilly's Verzenio Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 (C)2019 ENPublishing - http://www.enpublishing.co.uk Release date- 30072019 - INDIANAPOLIS - Eli Lilly [...]

ENPNewswire-October 16, 2017--VERZENIO Approved for Treatment of Metastatic Breast Cancer Available for Order at Biologics Inc. (C)2017 ENPublishing - http://www.enpublishing.co.uk Release date- 13102017 - CARY, N.C. - Biologics, Inc., a [...]